Eris Lifesciences allots shares for Swiss Parenterals acquisition

Fund Raising View source PDF Explain this filing

ERIS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.1%Reaction day

₹1447.00

prior close

₹1447.00

announcement price

After-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)-1.1%+1.0% vs market

Pharmaceuticals peers, median of 158sector-0.8%+0.7% vs sector

On the reaction day the stock moved 1.0 pts more than Nifty Smallcap 250 and 0.7 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.0

10m

-0.6

15m

-0.3

30m

-0.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.1-1.1+1.0-0.8+0.7

Next day

-4.3-3.8-0.5-3.1-1.2

-4.6-4.5-0.1-4.1-0.6

-0.5-3.6+3.1-3.0+2.5

-4.6-5.5+0.9-4.3-0.3

-7.4-5.3-2.1-4.6-2.8

-7.6-3.6-4.1-4.0-3.6

15d

+1.8+0.9+1.0-1.1+3.0

-8.3-1.4-6.9-2.4-5.9

-11.0-9.0-2.0-9.4-1.6

-1.1+1.1-2.2-1.0-0.1

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 158Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Eris Lifesciences allotted 23,06,372 equity shares at INR 1835.35 each to Mr. Naishadh Shah via preferential issue, as consideration other than cash for acquiring his 30% stake in Swiss Parenterals. Swiss is now a wholly owned subsidiary. Paid-up share capital rose from 13.62 crore to 13.85 crore shares. Shares are subject to lock-in under SEBI rules.

Likely market impact

No fresh cash inflow. Minor share dilution from new equity. Strengthens portfolio with Swiss Parenterals as wholly owned subsidiary.